


Supplementary Figure S1. Kaplan-Meier estimation of Progression-free survival (PFS) measured from inclusion in patients with Exon 20 insertion (blue) and control (red) receiving first-line chemotherapy (Panel A) and receiving first-line TKIs (Panel B).



Supplementary Figure S2. Kaplan-Meier estimation of Progression-free survival (PFS) measured from inclusion in patients with Exon 20 insertion receiving platin-based chemotherapy alone (blue, n=19) and platin-based chemotherapy + bevacizumab (red, n= 8): PFS= 4.5 vs 11 months, respectively (p=0.1).